Home Newsfeeds Evercore ISI Group Assumes Hyatt Hotels at In-Line

Evercore ISI Group Assumes Hyatt Hotels at In-Line

Evercore ISI Group analyst Duane Pfenningwerth assumes Hyatt Hotels (NYSE:H) with a In-Line rating.

byBenzinga Newsdesk

July 11, 2022

1 minute read

Evercore ISI Group analyst Duane Pfenningwerth assumes Hyatt Hotels (NYSE:H) with a In-Line rating.

Analyst Ratings

Analyst Expectations for Nyxoah’s Future

By Benzinga Insights

December 11, 2:00 PM

Over the past 3 months, 4 analysts have published their opinion on Nyxoah (NASDAQ:NYXH) stock. These analysts are…

NYXH

Morgan Stanley Maintains Overweight on Hippo Holdings, Adjusts PT To $51.5 (1-for-25 reverse stock split)

By Benzinga Newsdesk

September 30, 8:35 AM

Morgan Stanley analyst Michael Phillips maintains Hippo Holdings (NYSE:HIPO) with a Overweight, adjusts PT to $51.5 (1-for-25 reverse stock split).

HIPO

Safety Shot Continues Scientific Development With Double-Blind Placebo-Controlled Trial Designed To Assess The Effects Of Safety Shot On Blood And Breath Alcohol Levels; Topline Data Expected Q1 2024

By Benzinga Newsdesk

November 24, 9:33 AM

Topline data expected Q1 2024Safety Shot is designed to make you feel good faster by reducing blood alcohol levels and improving clarityA double-blinded, placebo controlled, clinical trial designed to compare the effects

SHOT

Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month

By Vandana Singh

February 9, 3:24 PM

"Bausch + Lomb's Q4 & FY 2023 results on Feb 21, 2024. Expecting $1.107 billion in sales, $0.17 EPS. RBC Capital predicts $1.159 billion revenue. Insights on Miebo launch and enhanced EBITDA margins for 2024.

ALC

Evercore ISI Group Assumes Hyatt Hotels at In-Line

Related Posts

Analyst Expectations for Nyxoah’s Future

Morgan Stanley Maintains Overweight on Hippo Holdings, Adjusts PT To $51.5 (1-for-25 reverse stock split)

Safety Shot Continues Scientific Development With Double-Blind Placebo-Controlled Trial Designed To Assess The Effects Of Safety Shot On Blood And Breath Alcohol Levels; Topline Data Expected Q1 2024

Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month